I-Mab Announces Portfolio Prioritization of Givastomig (CLDN18.2 x 4-1BB Bispecific Antibody) as Lead Clinical Program
Portfolio Pulse from
I-Mab has prioritized its bispecific antibody, Givastomig, as its lead clinical program. The company has completed a dose escalation study and is conducting a dose expansion study, with data expected in 2025 and 2026. I-Mab has a cash balance of $184.4 million to support operations into 2027 and has restructured its operations to focus on the U.S. market.
January 06, 2025 | 12:15 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
I-Mab has prioritized Givastomig as its lead clinical program, with ongoing studies and data expected in 2025 and 2026. The company has a strong cash position to support operations into 2027 and has restructured to focus on the U.S. market.
The prioritization of Givastomig as the lead program and the completion of a dose escalation study indicate progress in I-Mab's clinical pipeline, which is positive for the company's future prospects. The strong cash position and focus on the U.S. market further support a positive outlook.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100